Dr. Dana C. Hilt, MD, boasts over 25 years of expertise in CNS drug development across all phases. He held key roles, including Chief Medical Officer, at various pharmaceutical companies like Frequency Therapeutics, Lysosomal Therapeutics, Guilford Pharmaceuticals, Ascend Pharmaceuticals, and Critical Therapeutics. With a medical degree from Tufts University School of Medicine and training in internal medicine at Harvard Medical School and neurology at Johns Hopkins Hospital, he's also contributed significantly in academia, conducting research and teaching. Noteworthy is his establishment of a Clinical Neuroscience Group at Amgen, focusing on neurotrophic factors' therapeutic potential in diseases like Parkinson’s. His vast experience underscores his prowess in advancing treatments for complex neurological conditions.